Greenwich LifeSciences Leadership Extends Share Lock-Up Through 2026, Signaling Confidence in Clinical Trials
Stafford, Monday, 29 December 2025.
Directors voluntarily extended share restrictions through September 2026. This unprecedented six-year lock-up underscores strong insider confidence in the FLAMINGO-01 breast cancer trial’s potential.
Strategic Alignment with Clinical Timelines
On December 29, 2025, Greenwich LifeSciences, Inc. (GLSI) solidified its leadership’s commitment to the company’s long-term vision by announcing an extension of the share lock-up agreement for its directors, officers, and pre-IPO investors [1]. The new agreement prevents these insiders from selling their shares until September 30, 2026, a date that marks approximately 72 months since the company’s initial public offering [1]. Following this expiration, any sale of previously locked-up shares will be governed by a leak-out plan, subject to modification by the Board of Directors [1]. CEO Snehal Patel described this extension as an “unprecedented” six-year lock-up, explicitly designed to align the interests of locked-up shareholders with long-term investors while providing stability during the ongoing FLAMINGO-01 Phase III clinical trial [1].
Clinical Milestones Anchoring Investor Sentiment
The primary catalyst behind this extended lock-up is the progress of the FLAMINGO-01 Phase III trial, which is evaluating GLSI-100 for the prevention of breast cancer recurrences [1]. To date, the company has screened over 1,000 patients for the trial, maintaining a screening rate of approximately 600 patients annually [1]. Crucially, the non-HLA-A02 arm of the study, comprising 250 patients, is now fully enrolled, with all participants receiving the GLSI-100 treatment [1]. Early data from this fully enrolled arm appears promising; a preliminary analysis indicates an approximate 80% reduction in recurrence rates among patients in the non-HLA-A02 arm following the Primary Immunization Series [1]. This efficacy signal is consistent with previous findings, where HER2/neu 3+ patients treated with GLSI-100 demonstrated an 80% or greater reduction in cancer recurrences after five years of follow-up [1].
Market Position and Financial Outlook
The market has responded to the company’s recent developments with significant upward momentum. As of the close of trading on December 26, 2025, GLSI stock was priced at $20.68, representing a daily increase of 20.19% [2]. This surge brought the share price up from $17.21 recorded on December 24, 2025 [2]. From a financial reporting perspective, the company recently disclosed its third-quarter earnings on November 14, 2025, reporting an Earnings Per Share (EPS) of -$0.30, which aligned with analyst estimates [3]. By extending the lock-up period, Greenwich LifeSciences has effectively removed the risk of significant insider selling until the latter half of 2026, ensuring that management’s financial incentives remain tethered to the success of the FLAMINGO-01 trial [1].